Evidence map›Paper›PMID 31446480›Full record

Observational studyInternational journal of colorectal disease2019

Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model.

Andreas Stallmach, Bernd Bokemeyer, Ulf Helwig, Andreas Lügering, Niels Teich, Imma Fischer, Stefan Rath, Dorothee Lang, Carsten Schmidt, EPIC Study Group

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International journal of colorectal disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Andreas StallmachClinic for Internal Medicine IV, Jena University Hospital, Jena, Germany. andreas.stallmach@med.uni-jena.de.
Bernd BokemeyerGastroenterology Practice, Minden, Germany.
Ulf HelwigInternistische Praxisgemeinschaft Oldenburg, Oldenburg, Germany.
Andreas LügeringMVZ Portal 10, Münster, Germany.
Niels TeichInternistische Gemeinschaftspraxis, Leipzig, Germany.
Imma FischerBiostatistik Tübingen, Tübingen, Germany.
Stefan RathMedical Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
Dorothee LangMedical Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
Carsten SchmidtClinic for Internal Medicine IV, Jena University Hospital, Jena, Germany.ORCID http://orcid.org/0000-0002-3022-2021
EPIC Study Group
Jena University Hospital · DEAbbVie (Germany) · DEMedizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer · DEJohannes Wesling Klinikum Minden · DE

Funding

AbbVie Deutschland unknown
6 · The paper itself

Abstract

purposeThe aim of our study was to identify clinical parameters in recently diagnosed Crohn's disease (CD) patients for prediction of their disease course.

methodsEPIC (Early Predictive parameters of Immunosuppressive therapy in Crohn's disease) is a prospective, observational study in 341 patients with a recent CD diagnosis (≤ 6 months), and naïve to immunosuppressants (IS) and anti-tumor necrosis factor α (TNF) agents. Patient characteristics were documented up to 2 years. In line with national and international guidelines, a complicated disease course was defined as need for immunosuppressants and/or anti-TNF agents, and CD-related hospitalization with or without immunosuppressants and/or anti-TNF agents.

resultsA total of 212 CD patients were analyzed of whom 57 (27%) had an uncomplicated disease within 24 months, while 155 (73%) had a complicated disease course: need for IS and/or anti-TNF agents (N = 115), CD-related hospitalization with or without IS/anti-TNF agents (N = 40). Identified risk predictors for a complicated disease were as follows: age at onset < 40 years (OR 2.3; 95% CI 1.2-4.5), anemia (OR 2.1; 95% CI 1.1-4.2), and treatment with systemic corticosteroids at first flare (OR 2.2; 95% CI 1.1-4.7). These three parameters were used to develop a risk model allowing prediction of the future disease course.

conclusionOur three-parameter model enables an assessment of each CD patient's risk to develop a complicated disease course. Due to the easy accessibility of these parameters, this model can be utilized in daily clinical care to assist selecting the initial treatment for each individual patient.

Indexed as

Disease ProgressionModels, BiologicalAdultCrohn DiseaseEndpoint DeterminationHumansRisk FactorsAnti-TNF therapyCrohn’s diseaseDisease courseImmunosuppressive therapyPredictors

Identifiers

PMID31446480
OpenAlexW2969430619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.